Aileron Therapeutics (NASDAQ:ALRN) Earns Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Aileron Therapeutics (NASDAQ:ALRN) in a report published on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $2.00 target price on the stock.

A number of other research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Aileron Therapeutics from a buy rating to a hold rating in a research note on Tuesday, June 2nd. William Blair reiterated a buy rating on shares of Aileron Therapeutics in a research note on Friday, April 24th. Finally, Canaccord Genuity reiterated a buy rating on shares of Aileron Therapeutics in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $3.50.

Shares of ALRN opened at $1.13 on Monday. The stock has a market cap of $43.14 million, a price-to-earnings ratio of -1.09 and a beta of 3.73. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.46. Aileron Therapeutics has a 12 month low of $0.25 and a 12 month high of $1.99. The company has a 50-day moving average price of $1.08 and a two-hundred day moving average price of $0.70.

Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). Equities research analysts expect that Aileron Therapeutics will post -0.67 EPS for the current fiscal year.

In related news, Director Rickenbach Josef H. Von acquired 227,272 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was purchased at an average price of $1.10 per share, for a total transaction of $249,999.20. Following the transaction, the director now directly owns 445,460 shares of the company’s stock, valued at approximately $490,006. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Game Plan Financial Advisors LLC bought a new position in Aileron Therapeutics in the 4th quarter worth approximately $29,000. Geode Capital Management LLC raised its position in Aileron Therapeutics by 67.1% in the 4th quarter. Geode Capital Management LLC now owns 91,895 shares of the company’s stock worth $52,000 after purchasing an additional 36,893 shares during the last quarter. Banco Bilbao Vizcaya Argentaria S.A. bought a new position in Aileron Therapeutics in the 4th quarter worth approximately $57,000. Blair William & Co. IL raised its position in Aileron Therapeutics by 632.7% in the 4th quarter. Blair William & Co. IL now owns 348,044 shares of the company’s stock worth $199,000 after purchasing an additional 300,544 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in Aileron Therapeutics by 44.3% in the 4th quarter. Renaissance Technologies LLC now owns 491,081 shares of the company’s stock worth $281,000 after purchasing an additional 150,833 shares during the last quarter. Hedge funds and other institutional investors own 6.37% of the company’s stock.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Recommended Story: Backdoor Roth IRA

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.